GENERALIZED MYASTHENIA GRAVIS (MG)." Clinical Trials

26 clinical trials for GENERALIZED MYASTHENIA GRAVIS (MG)." across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DESCARTES-08 IN PATIENTS WITH ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS — RECRUITING · PHASE3
• AN OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND ACTIVITY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING
• A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, PARALLEL-GROUP DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV IN ADULT PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR BINDING ANTIBODY SERONEGATIVE GENERALIZED MYASTHENIA GRAVIS — RECRUITING · PHASE3
• A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER, FOLLOW-ON TRIAL OF ARGX- 113-2006 TO EVALUATE SAFETY OF EFGARTIGIMOD ADMINISTERED INTRAVENOUSLY IN CHILDREN WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ALXN1720 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING · PHASE3
• A PHASE 3, MULTI-CENTER, RANDOMIZED, QUADRUPLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BATOCLIMAB AS INDUCTION AND MAINTENANCE THERAPY IN ADULT PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG) — RECRUITING · PHASE3
• OPEN-LABEL UNCONTROLLED TRIAL TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND ACTIVITY OF EFGARTIGIMOD IN CHILDREN FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING
• EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY AND CEMDISIRAN MONOTHERAPY IN PATIENTS WITH SYMPTOMATIC GENERALIZED MYASTHENIA GRAVIS — RECRUITING
• A PHASE 3B, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE DIFFERENT DOSING REGIMENS OF INTRAVENOUS EFGARTIGIMOD TO MAXIMIZE AND MAINTAIN CLINICAL BENEFIT IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING · PHASE3
• AUTOLOGOUS T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED TO B-CELL MATURATION ANTIGEN (BCMA) IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG). — RECRUITING
• PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS — RECRUITING · PHASE3
• A PHASE III, OPEN-LABEL EXTENSION OF ECU-MG-301 TO EVALUATE THE SAFETY AAND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG) — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG) — RECRUITING
• A PHASE 3 GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CLASEPRUBART (DNTH103) IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (EMERGE) — NOT_YET_RECRUITING · PHASE3
• A PHASE 1B/2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE A) THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF IM-101 IN ADULT PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS, AND B) THE EFFICACY AND SAFETY OF TREATMENT OF IM-101 IN ADULT PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS AND OCULAR MYASTHENIA GRAVIS — NOT_YET_RECRUITING · PHASE1
• A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF INEBILIZUMAB IN CHILDREN FROM 2 YEARS TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS (GMG) — COMPLETED · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF IPTACOPAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS, FOLLOWED BY AN OPEN-LABEL EXTENSION PHASE — NOT_YET_RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF TELITACICEPT IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS — NOT_YET_RECRUITING · PHASE3
• A PHASE 2, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC) — COMPLETED · PHASE2
• AN OPEN-LABEL, CROSSOVER STUDY TO EVALUATE ROZANOLIXIZUMAB SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS — COMPLETED
• A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 3 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS — NOT_YET_RECRUITING · PHASE3
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS — COMPLETED
• A RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS - PHASE 3 — COMPLETED · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS - PHASE 3 — COMPLETED · PHASE3
• EFFICACY OF OPIOID-FREE ANESTHESIA IN REDUCING POSTOPERATIVE PAIN IN CHRONIC PAIN PATIENTS UNDERGOING SPINAL SURGERY: A PILOT STUDY. — NOT_YET_RECRUITING

Refine this search